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AbsTrACT
Objective To examine the association between age at 
period cessation and trajectories of anthropometry, blood 
pressure, lipids and glycated haemoglobin (hba1c) from 
midlife to age 69 years.
Methods We used data from the UK Medical research 
council national survey of health and Development to 
examine the association between age at period cessation 
and trajectories of systolic blood pressure (sBP), diastolic 
blood pressure (DBP), body mass index (BMi) and waist 
circumference (Wc) from 36 to 69 years and trajectories 
of triglyceride, low density lipoprotein cholesterol 
(lDl- c), high density lipoprotein cholesterol (hDl- c) and 
hba1c from 53 to 69 years.
results We found no evidence that age at period 
cessation was associated with trajectories of log 
triglyceride, lDl- c and hDl- c from 53 to 69 years 
and trajectories of sBP or DBP from 36 to 69 years, 
regardless of whether period cessation occurred naturally 
or due to hysterectomy. While we found some evidence 
of associations of age at period cessation with log BMi, 
log Wc and log hba1c, patterns were not consistent and 
differences were small at age 69 years, with confidence 
intervals that spanned the null value.
Conclusion how and when women experience period 
cessation is unlikely to adversely affect conventional 
cardiovascular risk factors across mid and later life. 
Women and clinicians concerned about the impact of 
type and timing of period cessation on conventional 
cardiovascular intermediates from midlife should be 
reassured that the impact over the long term is small.
InTrOduCTIOn
A recent systematic review and meta- analysis of 
observational studies showed that age at period 
cessation (natural and surgical combined) before 
45 years was associated with greater coronary heart 
disease (CHD) mortality, cardiovascular disease 
(CVD) mortality but not stroke mortality.1 Since that 
review, several other large studies have supported 
these findings,2–4 with one study suggesting a 
weaker association for age at surgical menopause 
than for age at natural menopause.2 Evidence for 
an inverse association of age at natural menopause 
and CVD risk is also supported by recent findings 
from a Mendelian randomisation study that showed 
that genetic variants associated with earlier age at 
natural menopause were associated with increased 
CVD risk in women.5
In contrast to the large body of literature demon-
strating inverse associations between age at period 
cessation and CVD risk and mortality, the afore-
mentioned systematic review1 highlighted a lack of 
studies focusing on age at period cessation and inter-
mediate risk factors such as body mass index (BMI), 
blood pressure and diabetes. Available longitudinal 
studies with repeated measures of CVD risk factors 
across midlife, such as the Study of Women’s Health 
across the Nation (SWAN) and Coronary Artery Risk 
Development in Young Adults (CARDIA)6–8 focused 
on acute and immediate changes close to the meno-
pausal transition rather than examining whether 
age at period cessation was associated with change 
over the long term.6–8 The few available studies 
that have examined intermediate risk factors have 
largely demonstrated a lack of association between 
age at period cessation and BMI, waist hip ratio, 
diastolic blood pressure (DBP), systolic blood pres-
sure (SBP), glucose, risk of diabetes, hypertension 
and obesity 9–13; however, these studies have mostly 
been cross- sectional and compared different groups 
of pre- and post- menopausal women, often with 
only a single measure of the intermediate risk factor 
and retrospective reports of age at period cessa-
tion in women who were already post- menopausal. 
Thus, prospective analyses of age at period cessa-
tion and change in CVD risk factors across midlife 
are required to clarify the association between age 
at period cessation and conventional CVD interme-
diates from midlife to older age; such analyses go 
beyond examination of age at period cessation and 
outcomes at a single time point, providing insights 
into whether trajectories of CVD risk factors from 
mid to later life differ by age at period cessation.
We examined the association between age at 
period cessation, by type of period cessation (hyster-
ectomy compared with natural menopause) and five 
repeated measures of blood pressure, BMI and waist 
circumference (WC) from age 36 to 69 years, and 
three measures of lipids and glycated haemoglobin 
(HbA1c) from age 53 until age 69 years, in the UK 
Medical Research Council (MRC) National Survey 
of Health and Development (NSHD).
MeThOds
Participants
The MRC NSHD is a socially stratified sample 
of 5362 subjects (2547 females and 2815 males) 
followed 24 times since birth in England, Scotland 
and Wales in the first week of March 1946, with an 
additional nine separate postal questionnaires sent 
to women in midlife.14 15 Ethical approval for the 
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years was given by Queen Square Research Ethics Committee 
(13/LO/1073) and Scotland A Research Ethics Committee (14/
SS/1009). Participants provided written informed consent for 
each visit.
data
Blood pressure and anthropometry
SBP, DBP, height, weight and WC were measured at 36, 43, 53, 
60–64 and 69 years. Blood pressure was measured at least twice 
at 36 and 43 years using a Hawksley Random Zero sphygmoma-
nometer16 and three times at ages 53, 60–64 and 69 years using 
an Omron HEM-705, while the study member was seated and 
after a short period of rest.17 Measurements from the Random 
Zero sphygmomanometer were adjusted using published conver-
sion equations to achieve compatibility with later measure-
ments.18 The second blood pressure reading was used unless 
it was missing, in which case the first was used. Height (cm), 
weight (kg) and waist (cm) were measured according to a stan-
dardised protocol at all home visits and the research clinic. BMI 
was calculated by dividing weight in kg by height in metres 
squared (kg/m2).
Lipids and HbA1c
Blood based markers (triglycerides, low density lipoprotein 
cholesterol (LDL- C), high density lipoprotein cholesterol 
(HDL- C) and HbA1c were measured at 53, 60–64 and 69 
years. A venous blood sample was taken by the nurse according 
to a standardised protocol at ages 53 (non- fasting),19 60–64 
(fasting)14 and 69 years (non- fasting).15 Total cholesterol was 
measured by enzymatic CHOD–PAP (cholesterol oxidase/perox-
idase aminophenazone). Triglycerides were measured using 
a glycerol/kinase POD linked reaction of glycerol liberated 
enzymatically from triglycerides; LDL- C was calculated using 
the Friedewald formula, and precipitation for measurement of 
HDL- C was performed using phosphotungstic Mg2+. All these 
measurements were made with a Bayer DAX-72. Samples were 
analysed for glycated haemoglobin with the Tosoh A1C 2.2 Plus 
Analyser (Tosoh, Tokyo, Japan) using high performance liquid 
chromatography.
Type and timing of menopause
Information on menstrual irregularity, month and year of last 
menstrual cycle or any operation to remove the uterus or ovaries 
and monthly hormone replacement therapy (HRT) use was 
obtained from annual postal questionnaires between the ages 
of 47 and 54 years (inclusive), with an additional one at 57 
years, and from the face to face interviews with nurses at 43, 
53 and 60–64 years.20 21 Age at which periods ceased naturally 
(defined as a period of at least 12 months without menstrua-
tion) or because of bilateral oophorectomy (with or without 
hysterectomy), or because of hysterectomy with or without 
unilateral oophorectomy was calculated. We excluded women 
whose periods stopped for other reasons, such as chemotherapy 
(n=37). We also excluded 189 women starting HRT before 
menopause who had not ceased HRT for at least a year before 
giving responses about period regularity and the timing of the 
last period because it was not possible to assign an accurate date 
of menopause among these women.
Potential confounders
We considered the following as potential confounders of the 
association between age at period cessation and CVD risk factors: 
socioeconomic position, parity, HRT use throughout follow- up, 
age at menarche, smoking at 36 years and physical activity at 
age 36 years. BMI at 36 years was considered as an additional 
confounder for blood pressure, lipids and HbA1c. The 36 year 
measures were selected for BMI, smoking and physical activity 
because these measures represent pre- menopausal measures for 
most women. Further information can be found in supplemen-
tary eAppendix 1.
sample sizes
Of the original birth cohort of females (n=2547), 1666 women 
were eligible for inclusion in analyses of blood pressure and 
anthropometry and 1563 women were eligible for inclusion in 
analyses of lipids and HbA1c. Of these women, only participants 
with a known date of period cessation, at least one measure 
of the risk factor and complete data on all confounders were 
included in analyses. Supplementary eFigure 1 and eTable 1 
provide an overview of the study design and measures available.
Modelling of age-related change in risk factors
We used multilevel models to examine change over time in CVD 
risk factors,22 as performed previously in other cohorts.23–25 
Multilevel models estimate mean trajectories of the outcome 
(here CVD risk factors) while accounting for the non- 
independence (ie, clustering) of repeated measurements within 
individuals, change in scale and variance of measures over time 
and differences in the number and timing of measurements 
between individuals, using all available data from all eligible 
participants under a Missing at Random (MAR) assumption that 
the value of the missing risk factor can be predicted by other 
measured variables.26 Changes in triglyceride, LDL- C, HDL- C 
and HbA1c were modelled using a linear age term (two levels: 
measurement occasion and individual), allowing risk factors to 
change linearly from 53 to 69 years. Linear spline multilevel 
models (two levels: measurement occasion and individual) were 
used to model change in SBP, DBP, BMI and WC. Linear splines 
allow knot points to be fitted in order to derive different periods 
in which change is approximately linear. In this analysis, we fit a 
knot point at age 53 years resulting in two periods of change for 
SBP, DBP, BMI and WC from 36 to 53 years and from 53 to 69 
years. All trajectories were modelled in MLwiN version 2.36,27 
called from Stata version 1428 using the runmlwin command.27
Values of CVD risk factors that had a skewed distribution 
(BMI, WC, triglyceride, HBA1c) were (natural) log transformed 
before analysis. Further details of model selection are provided 
in the supplementary material (supplementary eAppendix 2) and 
model fit statistics are provided in supplementary eTables 2 and 
3.
We examined the association of age at period cessation and 
type of period cessation (hysterectomy compared with natural 
menopause) with trajectories of each risk factor. We included 
variables for type of period cessation and age at period cessation 
and their interaction with age. We also included an interaction 
term for age at period cessation and type of period cessation 
to examine whether the association of age at period cessation 
differed by type of period cessation. Age at period cessation was 
centred at the mean age of period cessation for the sample (age 
50 years). We also performed several additional and sensitivity 
analyses. Further details of these analyses can be found in the 
supplementary material (supplementary eAppendix 3).
resulTs
Of the 908/915 women included in the analyses of blood pressure 
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Table 1 Characteristics of participants included in primary analyses 
of anthropometry by menopause type (n=915)
natural menopause 
n=675 (n=672, 99.6% 
pre- menopausal at age 
36 years (first measure 
of WC/bMI))
hysterectomy n=240 
(n=215, 89.6% pre- 
menopausal at age 36 
years (first measure of 
WC/bMI))
n (%) n (%)
Household social class
  Professional/intermediate 256 (37.9) 76 (31.7)
  Skilled (non- manual) 241 (35.7) 80 (33.3)
  Skilled manual and partly 
skilled
132 (19.6) 70 (29.2)
  Unskilled 46 (6.8) 14 (5.8)
Parity
  0 100 (14.8) 15 (6.3)
  1 or 2 379 (56.2) 130 (54.2)
  3 or more 196 (29.0) 95 (39.6)
Current smoking at age 36 233 (34.5) 91 (37.9)
Physical activity at age 36
  Inactive 275 (40.7) 110 (45.8)
  Less active 167 (24.7) 53 (22.1)
  Most active 233 (34.5) 77 (32.1)
HRT use
  Age 36 4/652 (0.6) 5/235 (2.1)
  Age 43 15/623 (2.4) 17/228 (7.5)
  Age 53 91/512 (17.8) 101/174 (58.1)
  Age 60–64 9/498 (1.8) 22/173 (12.7)
  Age 69 8/465 (1.7) 8/168 (4.8)
Mean age at menarche (SD) 13.1 (1.3) 12.9 (1.1)
Mean age at period cessation 
(SD)
51.5 (3.9) 44.1 (6.2)
BMI, body mass index; HRT, hormone replacement therapy; WC, waist circumference.
Figure 1 Mean predicted confounder adjusted trajectories of SBP, 
DBP, log BMI and log WC from 36 to 69 years, by age at natural 
menopause. BMI and WC are natural log transformed. Trajectories 
adjusted for socioeconomic position, parity, time- varying hormone 
replacement therapy use, age at menarche, BMI at age 36 (SBP and DBP 
only), smoking at age 36, and physical activity at age 36. Trajectories 
for the 75th (age 52, green line), median (age 50, red line) and 25th 
percentile (age 49, blue line) of age at period cessation among women 
with a natural menopause. BMI, body mass index; CI, 95% confidence 
interval; DBP, diastolic blood pressure; SBP, systolic blood pressure; WC, 
waist circumference.
Figure 2 Mean predicted confounder adjusted trajectories of SBP, 
DBP, log BMI and log WC from 36 to 69 years, by age at hysterectomy. 
Trajectories adjusted for socioeconomic position, parity, time- varying 
hormone replacement therapy use, age at menarche, BMI at age 36 
(SBP and DBP only), smoking at age 36, and physical activity at age 36. 
Trajectories for the 75th (age 49, green line), median (age 45, red line) 
and 25th percentile (age 40, blue line) of age at period cessation among 
women with hysterectomy. BMI, body mass index; CI, 95% confidence 
interval; DBP, diastolic blood pressure; SBP, systolic blood pressure; WC, 
waist circumference.
36 years, when the first measure of these was available (99.6% 
of women who had a natural menopause and 89.6% of women 
who had a hysterectomy were pre- menopausal at this age). Of 
the 787 women included in analyses of lipids and HbA1c, 94% 
of women who underwent a hysterectomy had the surgery by 
53 years and 61% of women who underwent a natural meno-
pause were post- menopausal by age 53 years. Women who had a 
hysterectomy were more likely to be in a lower social class, have 
higher parity, higher prevalence of current smoking at age 36, 
higher prevalence of physical inactivity at age 36, higher preva-
lence of HRT use across all time points and lower mean age at 
menarche and age at period cessation compared with women 
who had a natural menopause (table 1).
Women included in analyses were likely to be in a higher social 
class, have lower smoking prevalence at age 36, lower HRT use 
from 53 to 69, and have undergone a hysterectomy compared 
with women excluded from analyses due to missing exposure, 
confounder and outcome data. However, women included in 
analyses did not differ in parity, physical activity, mean age at 
menarche, mean age at period cessation, mean BMI at age 36 
or mean SBP at age 36 compared with women excluded from 
analyses (supplementary eTable 4).
Age at period cessation
Age at period cessation was not associated with SBP and DBP at 
age 36 and change in these from 36 to 69 years in unadjusted 
(supplementary eTable 5) and confounder adjusted analyses 
(supplementary eTable 6 and figures 1 and 2). In unadjusted 
analyses (supplementary eTable 5), a 1 year older age at natural 
menopause was associated with higher log WC at age 36 years 
although with confidence intervals that spanned the null value; 
there was no evidence that older age at natural menopause was 
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Figure 3 Mean predicted confounder adjusted trajectories of lipids 
and HbA1c from 53 to 69 years, by age at natural menopause. HbA1c 
and triglyceride are natural log transformed. Trajectories adjusted for 
socioeconomic position, parity, time- varying hormone replacement 
therapy use, age at menarche, BMI at age 36, smoking at age 36, and 
physical activity at age 36. Trajectories for the 75th (age 52, green 
line), median (age 50, red line) and 25th percentile (age 49, blue line) 
of age at period cessation among women with a natural menopause. 
BMI, body mass index; CI, 95% confidence interval; HbA1c, glycated 
haemoglobin; HDL- C, high density lipoprotein cholesterol; LDL- C, low 
density lipoprotein cholesterol.
Figure 4 Mean predicted confounder adjusted trajectories of lipids 
and HbA1c from 53 to 69 years, by age at hysterectomy. HbA1c and 
triglyceride are natural log transformed. Trajectories adjusted for 
socioeconomic position, parity, time- varying hormone replacement 
therapy use, age at menarche, BMI at age 36, smoking at age 36, and 
physical activity at age 36. Trajectories for the 75th (age 49, green line), 
median (age 45, red line) and 25th percentile (age 40, blue line) of 
age at period cessation among women with hysterectomy. BMI, body 
mass index; CI, 95% confidence interval; HbA1c, glycated haemoglobin; 
HDL- C, high density lipoprotein cholesterol; LDL- C, low density 
lipoprotein cholesterol.
Figure 5 Mean predicted confounder adjusted trajectories of SBP, 
DBP, log BMI and log WC from 36 to 69 years, by type of period 
cessation. Trajectories adjusted for socioeconomic position, age at 
period cessation, parity, time- varying hormone replacement therapy 
use, age at menarche, BMI at age 36 (SBP and DBP only), smoking at 
age 36, and physical activity at age 36. BMI, body mass index; CI, 95% 
confidence interval; DBP, diastolic blood pressure; SBP, systolic blood 
pressure; WC, waist circumference.
difference at age 36 persisted at age 69 years, although with 
confidence intervals that spanned the null value. Conversely, a 
1 year older age at hysterectomy was associated with lower log 
WC at 36 and lower log WC at age 69 years, though with confi-
dence intervals that spanned the null value. The same patterns 
of association were observed between age at period cessation 
and log BMI at ages 53 and 69 years, although associations 
were weaker. Findings for log WC and log BMI were similar 
in confounder adjusted analyses (supplementary eTable 6 and 
figures 1 and 2).
Age at period cessation, whether due to natural menopause or 
hysterectomy, was not associated with log triglyceride, LDL- C 
and HDL- C from age 53 and change in these from 53 to 69 
years in unadjusted (supplementary eTable 7) or confounder 
adjusted analyses (supplementary eTable 8 and figures 3 and 4). 
In unadjusted analyses (supplementary eTable 7), age at natural 
menopause and age at hysterectomy were each associated with 
lower log HbA1c at age 53 years, although with confidence 
intervals that spanned the null value. However, a 1 year older 
age at natural menopause was associated with a faster increase 
in log HbA1c from 53 to 69 years such that by 69 years, older 
menopause was associated with higher log HbA1c, although 
confidence intervals spanned the null value. In contrast, older 
age at hysterectomy was associated with slightly slower increases 
in log HBA1c from 53 to 69 leading to lower log HBA1c at age 
69 years, although with a confidence interval that spanned the 
null value. Findings for log HbA1c were similar in confounder 
adjusted analyses (supplementary eTable 8 and figures 3 and 4).
Type of period cessation
Type of period cessation (hysterectomy compared with natural 
menopause) was not strongly associated with trajectories of SBP, 
DBP, log BMI and log WC from 36 to 69 years (supplementary 
eTable 9 and figure 5) in unadjusted and confounder adjusted 
analyses or with log triglyceride and LDL- C from 53 to 69 years 
(supplementary eTable 10 and figure 6). In unadjusted analyses, 
there was some evidence of faster increases in log HbA1c and 
faster decreases in HDL- C from 53 to 69 years among women 
who had a hysterectomy (supplementary eTable 10); however, 
these differences attenuated upon adjustment for confounders 
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Figure 6 Mean predicted confounder adjusted trajectories of lipids 
and HbA1c from 53 to 69 years, by type of period cessation. HbA1c 
and triglyceride are natural log transformed. Trajectories adjusted for 
socioeconomic position, age at period cessation, parity, time- varying 
hormone replacement therapy use, age at menarche, BMI at age 36, 
smoking at age 36, and physical activity at age 36. BMI, body mass 
index; CI, 95% confidence interval; HbA1c, glycated haemoglobin; 
HDL- C, high density lipoprotein cholesterol; LDL- C, low density 
lipoprotein cholesterol.
Additional and sensitivity analyses
We found little evidence that the association of age at hyster-
ectomy with any of the CVD risk factors varied by type of 
procedure (conservation of at least one ovary or bilateral oopho-
rectomy). Our findings were not altered when we accounted for 
treatment of lipids, HbA1c and blood pressure. In sensitivity 
analyses excluding women who had reached menopause after 53 
years, findings for the association of age at period cessation or 
type of period cessation with CVD risk factors were not appre-
ciably altered compared with our primary analyses; all these 
results are available on request from the authors.
dIsCussIOn
In a British birth cohort with prospective assessment of age at 
period cessation and repeated measures of eight conventional 
CVD intermediates from 36/53 to 69 years, we found little 
evidence of associations between age at period cessation or type 
of period cessation and trajectories of anthropometry and blood 
pressure (from 36 years) and lipids and HbA1c (from 53 years) 
up to age 69 years.
Comparison with other studies
A lack of studies focusing on intermediate CVD risk factors was 
highlighted in the most recent systematic review of age at period 
cessation and CVD.1 Our findings are comparable with the few 
available studies of intermediate CVD risk factors included in 
that review. For example, in a cross- sectional study of Chinese 
women aged 40 to 59 years (n=2498 post- menopausal women 
and n=2245 pre- menopausal women), age at natural meno-
pause was not associated with any intermediate risk factors 
studied, including risk of hypertension, diabetes, dyslipidaemia 
and obesity or mean differences in SBP, DBP, BMI, total choles-
terol, triglyceride, HDL- C, LDL- C and glucose.12 In the Japan 
Nurses’ Health Study, another cross- sectional study of 22 426 
women, age at natural menopause (categorised as <45, 45 
to 53 and >53) was not associated with risk of hypertension 
or diabetes, but early menopause was associated with risk of 
hypercholesterolaemia,29 which contrasts with our findings that 
showed no strong evidence of associations of age at period cessa-
tion with lipids in later life. Our findings showing that the type 
of period cessation (hysterectomy compared with natural meno-
pause) was not associated with CVD risk factors are also compa-
rable to findings from the SWAN7 and CARDIA8 studies, which 
were of similar design to ours and included repeated measures 
of risk factors across the menopausal transition. However, our 
study examines change across a wider age range and into the 
seventh decade of life, demonstrating that type and timing of 
period cessation are not associated with CVD risk factors once 
all women have passed through menopause and reach older ages 
where CVD is more common.
Implications
If associations of age at period cessation and CVD events are 
causal and not the result of confounding in observational 
studies1 or shared genetic architecture of age at period cessa-
tion and CVD,5 our findings would suggest that changes in 
conventional CVD intermediates over the long term are an 
unlikely mediating pathway. The findings also have important 
implications for women and clinicians, as they suggest that any 
impact of age and type of period cessation on conventional CVD 
intermediates over the long term is likely to be small. However, 
studies with larger sample sizes in more heterogeneous popula-
tions are required to replicate our findings and provide more 
precise estimates of associations. Furthermore, some studies 
have shown that older age at period cessation may be associated 
with reduced risk of carotid atherosclerosis.1 Thus, there may 
still be associations with other CVD intermediates that have not 
been evaluated here, such as coronary artery calcification and 
vascular structure and function. 1 Further work examining age 
at period cessation and other CVD intermediates such as these 
may help to further elucidate the mechanisms underlying age at 
period cessation and CVD risk.
To aid interpretation, our findings should be considered in the 
context of the acute but transient changes in lipids observed close 
to the time of menopause in previous cohorts such as SWAN6 and 
the Women's Midlife Health Project.30 Although neither of these 
cohorts directly examined age at period cessation and change 
in CVD risk factors, it is possible that age at period cessation is 
associated with incident CVD risk not through a long- term effect 
on CVD risk factors but through acute effects on risk factors, 
which eventually attenuate over time. These acute effects close to 
the time of menopause may be clinically relevant for later CVD 
risk. Longitudinal cohorts examining age at period cessation and 
acute effects on intermediate risk factors close to the menopausal 
transition are required to provide a greater understanding of the 
aetiology of age at period cessation and CVD events, if reported 
associations in observational studies1 are causal.
strengths and limitations
There are several strengths to our study including the prospective, 
detailed and longitudinal collection of data on menopausal char-
acteristics and CVD measures from 36 and 53 years. Our study is 
the first to our knowledge to examine the association of type and 
timing of period cessation with CVD risk factors into the seventh 
decade of life. We have included women who have undergone 
hysterectomy and who were taking HRT, which many previous 
analyses have excluded. We have captured the full range of ages 
at which menopause occurs, a strength over previous analyses 
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ages at period cessation. We have used multilevel models which 
take account of clustering of repeated measures within indi-
viduals and the correlation between measures over time, and 
performed several sensitivity analyses to examine the robustness 
of our findings to the effect of pharmacological treatment of risk 
factors. Limitations include combining non- fasting and fasting 
bloods for risk factors and the availability of measures from 36 
years for only four out of the eight risk factors, as data for lipids 
and HbA1c were only available from the age of 53 years. Selec-
tion bias is also a potential limitation and individuals included 
in our analysis were more advantaged than those excluded 
due to missing exposure, outcome and confounder data, thus 
limiting the potential generalisability of our findings to the wider 
population.
COnClusIOn
How and when women experience period cessation is unlikely to 
adversely affect conventional CVD intermediates from midlife. 
Women and clinicians concerned about the impact of type and 
timing of period cessation on conventional CVD intermediates 
from midlife should be reassured that the impact over the long 
term is likely to be small.
Key messages
What is already known on this subject?
 ► Age at period cessation is associated with cardiovascular 
disease (CVD). Whether age at period cessation adversely 
affects change in conventional CVD intermediates from mid 
to later life is not well understood.
What might this study adds?
 ► Using data from the 1946 British birth cohort study with 
prospective measurement of type and timing of period 
cessation and repeated measures of CVD risk factors from 
midlife to age 69 years, our findings suggest that the impact 
of type and timing of period cessation on conventional CVD 
intermediates from midlife is likely to be small over the long 
term.
how might this impact on clinical practice?
 ► Clinicians may be able to reassure women that the impact of 
type and timing of period cessation on conventional CVD risk 
factors such as blood pressure and lipids from midlife to age 
69 years is likely to be small.
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